Tree Canopy Gains Linked to Lower Mortality - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Tree Canopy Gains Linked to Lower Mortality

The association was most pronounced in Chicago’s hottest neighborhoods, where canopy losses were linked to higher predicted mortality.

  • By

  • Teraya Smith

  • August 11, 2026

  • 3 min

Share

Clinical Scorecard: Tree Canopy Gains Linked to Lower Mortality

At a Glance

CategoryDetail
ConditionUrban Tree Canopy Impact on Mortality
Key MechanismsYear-to-year increases in tree canopy associated with lower all-cause and cause-specific mortality.
Target PopulationResidents of Chicago neighborhoods
Care SettingUrban environmental health research

Key Highlights

  • 1% increase in tree canopy linked to approximately 10% lower all-cause mortality.
  • Significant associations observed for cardiovascular, respiratory, and mental health-related deaths.
  • Greater canopy losses correlated with higher mortality in hotter neighborhoods.
  • Model estimates suggest 14,000 new trees could prevent about 105 deaths annually.
  • Study could not establish causality; limitations include lack of individual long-term exposure data.

Guideline-Based Recommendations

Diagnosis

    Management

    • Protect tree canopy cover, especially in vulnerable areas with higher temperatures.

    Monitoring & Follow-up

      Risks

      • Potential for higher mortality rates in neighborhoods with greater canopy loss.

      Patient & Prescribing Data

      Urban residents in areas with varying tree canopy levels.

      Increasing urban tree canopy may contribute to lower mortality rates.

      Clinical Best Practices

      • Integrate urban forestry initiatives into public health strategies.
      • Conduct spatial analyses to identify neighborhoods at risk due to canopy loss.

      Related Resources & Content

      Original Source(s)

      Tree Canopy Gains Linked to Lower Mortality

      • by Teraya Smith

      • August 11, 2026

      Related Content

      FDA Approves First Oral PCSK9 Inhibitor

      Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

      Effect of Socioeconomic Status on SGLT2 Initiation in Heart Failure

      A nationwide German claims analysis found lower initiation of guideline-recommended sodium-glucose cotransporter-2 inhibitors among women and patients living in lower-income municipalities.

      Synthetic Echo Motion May Aid ECG Risk Modeling

      An ensemble electrocardiogram model classified derived diastolic dysfunction risk phenotypes and stratified heart failure–related death risk across external cohorts, according to findings presented at ASE 2026.